Publications by authors named "Munzur-E-Murshid"
Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence.
View Article and Find Full Text PDFArticle Synopsis
- The prevalence of diabetes is rising, leading to increased healthcare costs and complications associated with poor glycaemic control, particularly hypoglycaemia.
- Long-acting insulin analogues, while improving adherence and reducing hypoglycaemia, are expensive, making their use challenging in low and middle-income countries, despite the potential of biosimilars to lower costs.
- A study across six Asian countries found increased use of long-acting insulin analogues, especially biosimilars in Bangladesh, India, and Malaysia, but limited usage in Pakistan due to affordability issues.
Background: Prevalence rates of patients with diabetes are growing across countries, and Bangladesh is no exception. Associated costs are also increasing, driven by costs associated with the complications of diabetes including hypoglycemia. Long-acting insulin analogues were developed to reduce hypoglycemia as well as improve patient comfort and adherence.
View Article and Find Full Text PDF